The evolution of therapeutic modalities drives the adoption of single-use technologies.

Review of SUT Adoption in Biopharma Manufacturing

Despite its understandable hesitancy, the pharma industry is facing a need for more widespread adoption of cloud-based solutions.

Why Are Pharmaceutical Companies Reluctant to Adopt Cloud Technologies?

Given the criticality of fill/finish processes, it is clear that automation is the next technological step.

 Automating the Future of Fill/Finish

Topic

Jeff Odum, CPIP, is practice lead, ATMPs & Biologics, at Genesis AEC.

Articles

A combination of rapid sterility methods with the industry standard compendial method should ensure maximum safety.

Exploring Multimodal Biomanufacturing and Its Drivers

The new 80,000-square-foot facility will increase production of the company’s freeze-drying equipment.

IMA Life North America Breaks Ground on New Facility in Tonawanda, NY

Ramesh Raju Mavuleti*, rrajum@gmail.com, is head of operations, Validation Services India, at Merck Life Sciences Pvt, Ltd.

K. Vasantakumar Pai, PhD , is professor and chairman, PG Department of studies & research in Industrial Chemistry, Kuvempu University

K. Sreedhara Ranganath Pai, PhD, is professor, epartment of Pharmacology, Manipal Academy of Higher Education

Subhasis Banerjee, PhD, is principal technical application expert, Bioprocessing APAC, at Merck Life Sciences Pvt, Ltd.

Somasundaram Gopalakrishnan, is senior consultant, Global Biopharm Center of Excellence, Merck Pte. Ltd.

Tathagata Ray is Area Manager, Process Development at Millipore India Pvt. Ltd (India).

Determining E&L risk from single-use components can be used to build the level of extractable profiling and PERLs.

Application of the Risk Evaluation Matrix as per USP <665> and <1665> for Evaluation of Leachables Risk from Single-Use Components Used in Biomanufacturing

The drug discovery company intends for this new site to increase its reach in the region, supporting growing demands from its Asia-Pacific consumers.

Cresset to Open New Headquarters in Bangalore, India

Webcasts

Webinar Date/Time: Wednesday, June 5, 2024 at 11am PDT | 2pm EDT



Is Your Cleanroom Apparel a Risk to Your Contamination Control Strategy?

The separation of deamidated capsids from non-deamidated capsids can be achieved using HIC, according to studies done by a team at Oxford Biomedica.

Research Shows that HIC Can Effectively Separate Deaminated Capsids from Non-Deaminated Capsids (ASGCT 2024)

Feliza Mirasol is the science editor for 

Videos

Phillip Gregory, PhD, senior vice-president and head of Regeneron Cell Medicines, Regeneron, discussed how engineering receptor architecture can be a tool to improve CAR-T cell sensitivity to tumor antigens.

Using Receptor Architecture to Improve CAR-T Cell Sensitivity in Oncology (ASGCT 2024)

Regeneron's Sven Moller-Tank, PhD, director of Viral Delivery Technologies, Regeneron Genetic Medicines, discusses the company's work in using bispecific antibodies for redirecting AAV target specificity.

The Role of Bispecific Antibodies in Redirecting AAV Vectors (ASGCT 2024)

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

A greater understanding of molecular and cellular biology and technological advancements are revolutionizing the field of biologics. 

Biologics on Target for the Future

Experiments conducted by the downstream technology team at Spark Therapeutics involving metal ion-containing additives showed improved capsid clearance in AAV production.

ASGCT 2024: Additives Play a Role in Removal of Empty and Partial AAV Capsids

Aseptic/Sterile Processing

Cleanroom Equipment and Supplies

Clinical Trial Materials